PT217

Stay updated on biopharmaceutical advancements with the Synapse database, offering daily or weekly insights into drugs, targets, indications, and organizations.

The FDA fast-tracked PT217 for metastatic neuroendocrine prostate cancer. PT217, a DLL3/CD47-targeting antibody, is in the SKYBRIDGE trial for DLL3-expressing cancers like SCLC, LCNEC, and EP-NEC, either as monotherapy or with atezolizumab. The trial's primary endpoints include safety, tolerability, and PFS, with biomarkers as exploratory endpoints. PT217 also received fast-track designation for ES-SCLC in 2024 and orphan drug designations for SCLC and NEC.

The FDA granted fast track designation to PT217, a DLL3- and CD47-targeting antibody for metastatic neuroendocrine prostate cancer. PT217 also received orphan drug designation for neuroendocrine carcinoma in August 2024. The phase 1/2 SKYBRIDGE trial is evaluating PT217's safety, tolerability, and efficacy in neuroendocrine cancers, including neuroendocrine prostate cancer and small cell lung cancer. The trial, set to complete by December 2027, involves 203 patients across 7 US sites and includes combination therapy phases with atezolizumab and chemotherapy.

Phanes Therapeutics announced FDA Fast Track designation for PT217 in metastatic neuroendocrine prostate cancer (NEPC), marking the second such designation for PT217. PT217, a first-in-class bispecific antibody targeting DLL3 and CD47, is also being developed for small cell lung cancer (SCLC) and neuroendocrine carcinoma, with orphan drug designations granted for both. The SKYBRIDGE study, a Phase I/II trial, is evaluating PT217's safety and efficacy in advanced cancers expressing DLL3.

Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track Designation for treating neuroendocrine prostate cancer (NEPC). PT217 is also being evaluated in Phase I/II trials for advanced cancers expressing DLL3, with ongoing studies in China and a collaboration with Roche for combination therapy.

Phanes Therapeutics' PT217 granted Fast Track designation by FDA for metastatic neuroendocrine prostate cancer (NEPC). PT217 is a first-in-class bispecific antibody targeting DLL3 and CD47, also granted orphan drug designations for small cell lung cancer and neuroendocrine carcinoma.

Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, receives FDA Fast Track designation for metastatic NEPC, with orphan drug designations for SCLC and neuroendocrine carcinoma. A Phase I/II trial (SKYBRIDGE) is assessing its safety and efficacy in advanced DLL3-expressing cancers.

Phanes Therapeutics announces FDA Fast Track designation for PT217 in metastatic neuroendocrine prostate cancer (NEPC), the second such designation for PT217. PT217, a first-in-class bispecific antibody targeting DLL3 and CD47, is also being developed for small cell lung cancer (SCLC) and neuroendocrine carcinoma, with orphan drug designations granted for both. A Phase I/II clinical trial (SKYBRIDGE study) is ongoing to evaluate PT217's safety and efficacy in advanced cancers expressing DLL3.

Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received its second FDA Fast Track designation for treating neuroendocrine prostate cancer (NEPC). It also has orphan drug designations for small cell lung cancer and neuroendocrine carcinoma. PT217 is under evaluation in Phase I/II trials for advanced cancers expressing DLL3.